Immuron Updates At-The-Market Funding Facility Melbourne, Australia – 27 October 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian- based and globally integrated biopharmaceutical company, advises that it has filed a Prospectus Supplement with the U.S. Securities and Exchange...